Preserve the result.
Interpret available biomarkers, values, and testing context for more consistent use.
Prognos Oncology
A clearer clinical view.
A stronger oncology strategy.
Build commercial decisions around the biology that matters. Prognos brings harmonized lab findings and enriched context to market planning, launch strategy, and HCP engagement.
From broad markets to specific biology
Your oncology market is more than a diagnosis.
In precision oncology, a tumor type is often the starting point. Biomarkers, testing methods, and measured clinical findings can help define the population your team needs to understand.
Prognos turns complex lab records into a more consistent resource for commercial decisions. With harmonization, enrichment, and provider context, your team can spend more time evaluating the opportunity and less time reconciling the inputs.
Understand the clinical signal.
Bring that understanding into your strategy.
Bring that understanding into your strategy.
Choose your objective
Clinical depth.
Commercial relevance.
Start with the decision your team needs to make. Shape the data, enrichment, and delivery around it.
Plan the market
Build a strategy around the clinical reality.
Go beyond a diagnosis code to evaluate available biomarker findings, observed testing patterns, and the HCPs connected to the population you need to understand.
Use lab-defined cohorts and harmonized results to inform market assessment, segmentation, and prioritization.
Discuss your oncology priorities →- Which findings define the population relevant to your therapy?
- Where is relevant testing being observed?
- Which HCPs and accounts warrant a closer look?
Support the launch
Bring a more precise view to launch planning.
Use clinically specific lab findings and provider context to evaluate your target universe and prepare an engagement strategy around the population that matters to your brand.
Connect relevant lab signals with your planning foundation, then align delivery and enrichment to the launch workflow.
Discuss your oncology priorities →- How does a lab-informed HCP view compare with your target list?
- Which clinical findings should inform prioritization?
- How will signals reach the team that needs to use them?
Inform engagement
Give your team a clinically relevant reason to engage.
Bring observed lab findings into field and omnichannel workflows, with provider enrichment to help teams evaluate HCP relevance beyond the name on the original lab record.
Align clinical alerts and precision marketing to the intended workflow, with clear signal definitions and delivery expectations.
Discuss your oncology priorities →- Which lab event is relevant to the intended engagement?
- Which providers are connected to the observed clinical activity?
- What cadence and workflow will make the signal useful?
Examples of relevant inputsBiomarker resultsTesting methodologyObserved testing historyLinked provider context
The Prognos foundation
Lab data becomes more valuable
when the clinical meaning carries through.
Source-aware harmonization and clinically trained ML and AI models help standardize and enrich varied lab records into analysis-ready data. Your team gets a stronger foundation for the questions and workflows that follow.
Explore the data capabilities →Connect the context.
Add patient linkage and provider intelligence within the program’s scope.
Reduce fragmentation.
Use Prognos Fusion to harmonize participating licensed lab sources.
Fit the workflow.
Align delivery structure and cadence to the intended application.
From strategy to execution
Build on a connected
set of capabilities.
Combine the capabilities that fit your program, from clinically informed segmentation to field and omnichannel engagement.
Analytics & segmentation
Evaluate lab-defined populations and observed testing activity to support market understanding, HCP segmentation, and account prioritization.
Explore analytics →Care Team enrichment
Look beyond the ordering provider. Linked patient and provider activity can help teams evaluate which HCPs may be relevant to their program.
Explore Care Team →Clinical alerts & precision marketing
Use relevant lab signals to inform HCP engagement, audience strategy, and follow-up in field and omnichannel workflows.
Explore precision marketing →Prognos Fusion
Bring Prognos-licensed data and participating directly contracted lab feeds into a consistent structure, with harmonization and enrichment across sources.
Explore Fusion →Oncology focus
Start with the tumor type.
Go deeper into the question.
Explore relevant lab findings across solid tumors and hematologic malignancies. We can evaluate the sources, attributes, and provider context that fit your specific use case.
Discuss your priority indication →- Non-small cell lung cancer
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Ovarian cancer
- Multiple myeloma
- Acute myeloid leukemia
- Other hematologic malignancies
Oncology programs in practice
See how lab signals
support engagement.
Explore two oncology alert programs and the role of timely clinical data, provider visibility, and field execution.
NSCLC · Field execution
Bringing relevant alerts into the field workflow.
A biopharmaceutical company used a lab-based HCP alert program to support engagement around clinically relevant oncology findings.
70–85%Alert execution within two days
for ROS1-positive cases
Read the NSCLC case study →for ROS1-positive cases
ALK-positive NSCLC · Early program results
Supporting engagement around a defined biomarker.
A global biopharmaceutical company implemented lab-based alerts to help its team identify relevant HCPs for an ALK-positive NSCLC program.
2New patient starts observed
in the first three weeks
Read the ALK-positive NSCLC case study →in the first three weeks
Looking for more detail on lab sources, clinical interpretation, provider enrichment, and connected delivery?
Explore Oncology Intelligence →A client perspective
Value the field
can recognize.
“The Prognos Alerts program is, without doubt, the most impactful marketing lever that we can pull.”Mid-tier Pharma · Brand Marketing
Start with your oncology priorities
What does your team
need to see more clearly?
Bring a tumor type, biomarker, or commercial objective. Let’s explore the lab findings and context that can help move your strategy forward.
Unlocking the Power of Data to Improve Health.